 CEL-SCI Corporation NASDAQ:CVM shares are trading lower by 27 at 9.33 on continued downward momentum following data from a Phase 3 Study of Multkine showing a 14.1 5-year survival benefit in groups receiving surgery and radiotherapy for cancer. CEL-SCI is a player in the biotechnology sector. 